GSK-3 Inhibitor X

An acetoxime analog of BIO, GSK-3 Inhibitor IX (Cat. No. 361550) that exhibits greater selectivity for GSK-3α/β (IC₅₀ = 10 nM) over Cdk5/p25, Cdk2/A and Cdk1/B (IC₅₀ = 2.4 µM, 4.3 µM and 63 µM, respectively). Weakly affects the activities of Cdk4/D1 and many other kinases (IC₅₀ ≥ 10 µM). Also acts as an aryl hydrocarbon receptor agonist in both yeast (EC₅₀ ≥ 0.1 µM) and mammalian (EC₅₀ = 0.16 µM) reporter systems.

An acetoxime analog of BIO, GSK-3 Inhibitor IX (Cat. No. 361550) that exhibits greater selectivity for GSK-3α/β (IC₅₀ = 10 nM) over Cdk5/p25, Cdk2/cyclin A, and Cdk1/cyclin B (IC₅₀ = 2.4 µM, 4.3 µM, and 63 µM, respectively). A weak inhibitor of Cdk4/cyclin D1 and many other non-related kinases (IC₅₀ ≥ 10 µM). Yields BIO (Cat. No. 361550) upon hydrolysis.

Cell permeable: no

Primary Target
GSK-3α/β

Product does not compete with ATP.

Reversible: no

Target IC₅₀: 10 nM against GSK-3α/β

Packaged under inert gas

Toxicity: Carcinogenic / Teratogenic (D)

Limited solubility in aqueous buffers; serial dilutions in DMSO may be required prior to dilution in buffer.

Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 1 month at -20°C.

Knockaert, M., et al. 2004. Oncogene23, 4400.
Polychronopoulos, P., et al. 2004. J. Med. Chem.47, 935.
Meijer, L., et al. 2003. Chem. Biol.10, 1255.

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany